Education
About Us
Working with TipRanks
Follow Us
Genomtec SA (DE:4VI)
FRANKFURT:4VI
4VI Stock Chart & Stats
€1.04
-€0.29(-15.16%)
At close: 4:00 PM EST
€1.04
-€0.29(-15.16%)
Day’s Range― - ―
52-Week Range€0.71 - €2.21
Previous CloseN/A
Volume0.00
Average Volume (3M)35.00
Market Cap
€17.52M
Enterprise Value€70.80M
Total Cash (Recent Filing)€7.40M
Total Debt (Recent Filing)€2.13M
Price to Earnings (P/E)―
Beta-0.03
Next Earnings
May 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding15,064,634
10 Day Avg. Volume0
30 Day Avg. Volume35
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)13.80
Price to Sales (P/S)104874.86
P/FCF Ratio-15.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
4VI FAQ
What was Genomtec SA’s price range in the past 12 months?
Genomtec SA lowest stock price was €0.71 and its highest was €2.21 in the past 12 months.
What is Genomtec SA’s market cap?
Genomtec SA’s market cap is €17.52M.
When is Genomtec SA’s upcoming earnings report date?
Genomtec SA’s upcoming earnings report date is May 05, 2026 which is in 56 days.
How were Genomtec SA’s earnings last quarter?
Genomtec SA released its earnings results on Nov 28, 2025. The company reported -€0.04 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.04.
Is Genomtec SA overvalued?
According to Wall Street analysts Genomtec SA’s price is currently Overvalued.
Does Genomtec SA pay dividends?
Genomtec SA does not currently pay dividends.
What is Genomtec SA’s EPS estimate?
Genomtec SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genomtec SA have?
Genomtec SA has 15,064,634 shares outstanding.
What happened to Genomtec SA’s price movement after its last earnings report?
Genomtec SA reported an EPS of -€0.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.142%.
Which hedge fund is a major shareholder of Genomtec SA?
Currently, no hedge funds are holding shares in DE:4VI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genomtec SA
Genomtec S.A. researches, develops, manufactures, and commercializes innovative molecular diagnostic products in optical systems and isothermal nucleic acid amplification methods in Poland and internationally. The company develops Genomtec ID, a technological device that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analyzing the biological material of patients using swabs, urine samples, saliva, blood, and other body fluids. It also develops Genomtec Tumor, a SNAAT based solution used to identify neoplastic mutations and mutations with prognostic value in neoplastic disease; Genomtec SARS-CoV-2 EvaGreen and Direct-RT-LAMP CE-IVD Kit to detect SARS-CoV-2 RNA in various biological samples from patients with suspected COVID-19 infection; and Genomtec RT-LAMP CE-IVD Duo-Kit for the detection of all variants of the SARS-CoV-2 virus. Genomtec S.A was founded in 2016 and is based in Wroclaw, Poland.
Technical Analysis
Biomaxima SA
―
Pure Biologics SA
―
Scope Fluidics SA
―
OncoArendi Therapeutics SA
―
Mabion SA
―